UY27170A1 - MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT - Google Patents

MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT

Info

Publication number
UY27170A1
UY27170A1 UY27170A UY27170A UY27170A1 UY 27170 A1 UY27170 A1 UY 27170A1 UY 27170 A UY27170 A UY 27170A UY 27170 A UY27170 A UY 27170A UY 27170 A1 UY27170 A1 UY 27170A1
Authority
UY
Uruguay
Prior art keywords
formulation containing
muscarinic agonist
agonist agent
medicinal formulation
agent
Prior art date
Application number
UY27170A
Other languages
Spanish (es)
Inventor
Karoline B Peters
Thomas Friedi
Michael Walz
Original Assignee
Boehringer Ingelheim Pharma
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY27170A1 publication Critical patent/UY27170A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

El invento se refiere a una nueva formulación de medicamento que contiene el agente agonista muscarínico talsaclidina y a un procedimiento para su preparaciónThe invention relates to a new medicament formulation containing the muscarinic agonist agent talsaclidine and to a process for its preparation.

UY27170A 2001-02-15 2002-02-13 MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT UY27170A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10106971A DE10106971A1 (en) 2001-02-15 2001-02-15 Drug formulation containing a muscarinic agonist

Publications (1)

Publication Number Publication Date
UY27170A1 true UY27170A1 (en) 2002-09-30

Family

ID=7674095

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27170A UY27170A1 (en) 2001-02-15 2002-02-13 MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT

Country Status (9)

Country Link
EP (1) EP1361871A2 (en)
JP (1) JP2004518710A (en)
AR (1) AR033862A1 (en)
AU (1) AU2002247705A1 (en)
CA (1) CA2434976A1 (en)
DE (1) DE10106971A1 (en)
MX (1) MXPA03007272A (en)
UY (1) UY27170A1 (en)
WO (1) WO2002064124A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101652139A (en) 2007-03-29 2010-02-17 第一三共株式会社 Pharmaceutical composition
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
WO2011115067A1 (en) 2010-03-19 2011-09-22 第一三共株式会社 Method for improving dissolvability of anticoagulant
WO2013022059A1 (en) 2011-08-10 2013-02-14 第一三共株式会社 Pharmaceutical composition containing diamine derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8817121U1 (en) * 1988-11-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim New quinuclidines
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
WO1998046601A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
WO1998046225A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Method for treating schizophrenia
DE19851126A1 (en) * 1998-11-06 2000-05-11 Boehringer Ingelheim Pharma Use of talsaclidine for treating schizophrenia

Also Published As

Publication number Publication date
DE10106971A1 (en) 2002-08-29
AR033862A1 (en) 2004-01-07
WO2002064124A3 (en) 2002-12-05
JP2004518710A (en) 2004-06-24
MXPA03007272A (en) 2003-12-04
WO2002064124A2 (en) 2002-08-22
EP1361871A2 (en) 2003-11-19
CA2434976A1 (en) 2002-08-22
AU2002247705A1 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
AR022008A1 (en) A COMPOSITION OF CONTROLLED GALANTAMINE RELEASE, A PROCESS FOR THE PREPARATION OF THE SAME, AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT
ATE304368T1 (en) MEDICINAL PRODUCTS CONTAINING HERBAL PLANTS
CL2009001279A1 (en) Nociceptin derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of pain (sol. divisional 2103-03).
BR0015188A (en) Pharmaceutical compositions
PA8575701A1 (en) ACID INSULIN PREPARATIONS WITH IMPROVED STABILITY
ECSP077999A (en) FORMULATIONS OF A MODIFIED LIBERATION BUPROPION SALT
FR2804025B1 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
BR0100554B1 (en) packaging and application device having a porous structure incorporating a biocidal agent.
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
ECSP066553A (en) MASTICABLE ADMINISTRATION FORMS, NOT INDIVIDUALLY DOSED COMPRESSED.
PL1845957T3 (en) Method for producing a drug extract that contains hydroxystilbenes
ECSP045493A (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERINE POLYMORPH A
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
DE69923336D1 (en) ORANGE BUPRENORPHINIC MEDICINAL PRODUCTS TO BE APPLIED
SG149054A1 (en) Multiparticulate formulations for oral delivery
ECSP066860A (en) ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA
AR032872A1 (en) COMPOSITION TO CLEAR THE SKIN AND APPLICATION METHOD
AR034813A1 (en) PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
AR028448A1 (en) FORMULATIONS CONTAINING A GLUCOCORTICOID DRUG FOR THE TREATMENT OF BRONCOPULMONARY DISEASES
BR0107899A (en) Process for producing an active ingredient preparation comprising ibuprofen, preparation of active ingredient, use thereof, pharmaceutical preparation, use thereof, process for producing solid dosage forms, and, solid dosage form
BRPI0412697A (en) pharmaceutical compositions having an expandable coating
AR026072A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING CICLESONIDE FOR MUCOSA APPLICATION
PA8548301A1 (en) PHARMACEUTICAL FORMULATION OF MASKED FLAVOR AND PROCEDURE FOR PREPARATION
UY30065A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE ERADICATION OF HELICOBACTER PYLORI

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141112